Similar Items: Global burden of metabolic dysfunction-associated steatotic liver disease attributable to tobacco, 1990–2023, and projected trends to 2038
- Metabolic dysfunction–associated steatotic liver disease and cardiovascular disease: Emerging insights into the liver–heart axis
- Trends in the incidence and prevalence of thyroid dysfunction over 18 years and projections for 2030: the Tehran thyroid study
- Advancing the Development of the China‐SCO Cooperation Center for Metabolic Diseases to Foster a Global Community of Health for All
- Factors affecting country differences in the prevalence of type 2 diabetes mellitus based on the global burden of disease data 2021: using multilevel longitudinal data analysis
- EXPRESSION OF CONCERN: Donor Liver Steatosis: A Risk Factor for Early New‐Onset Diabetes after Liver Transplantation
- Neuregulin 4‐dependent MAPK amplification mediates urate‐induced β‐cell dysfunction